ReviewFrontiers in gastroenterology (Lausanne, Switzerland)2024
Innate immune cells in the pathogenesis of inflammatory bowel disease - from microbial metabolites to immune modulation.
Review in Frontiers in gastroenterology (Lausanne, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Chemerin as a biomarker of inflammatory bowel diseases: a meta-analysis.BMC gastroenterology · 2025Pooled it
- Bioactive Anti-Inflammatory Compounds and Therapeutic Strategies for Promoting Resolution.Pharmaceutics · 2026Review
- From Chronic Inflammation to Cancer: The Role of Trained Immunity in IBD-Associated Colorectal Carcinogenesis.Medical sciences (Basel, Switzerland) · 2026Review
- Article
- Inflammatory, Nutritional, and Atherogenic Profiles Associated with Histologic Activity in Inflammatory Bowel Disease.Biomedicines · 2026Article
- Type 1 and CD103European journal of immunology · 2026Article
- A study on the role of Tai Chi training in improving type 2 diabetes mellitus.Frontiers in public health · 2026Article
- Drug-associated inflammatory bowel disease: a real-world pharmacovigilance study using the FAERS and JADER databases.Frontiers in immunology · 2026Article
- The Paradox of NET Involvement in the Pathogenesis of Inflammatory Bowel Disease.Inflammatory bowel diseases · 2026Review
- Diagnostic challenges and treatment approaches forFrontiers in microbiology · 2026Review
- Role of physical exercise, vagal nerve stimulation, and vagotomy in inflammatory bowel disease.World journal of gastroenterology · 2025Review
- The role of neutrophils in the pathophysiology of inflammatory bowel diseases.Periodontology 2000 · 2025Review
- Article
- Human Microbiome as an Immunoregulatory Axis: Mechanisms, Dysbiosis, and Therapeutic Modulation.Microorganisms · 2025Review
- The Role of Endometriosis in Intestinal Inflammation: A Combined Mendelian Randomization and Cellular Study.Journal of cellular and molecular medicine · 2025Article
- Efficacy of Biologic Agents and Small Molecules for Endoscopic Improvement and Mucosal Healing in Patients with Moderate-to-Severe Ulcerative Colitis: Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Galectin-3-Insights from Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.International journal of molecular sciences · 2025Review
- The Impact of Antibiotic Therapy on Intestinal Microbiota: Dysbiosis, Antibiotic Resistance, and Restoration Strategies.Antibiotics (Basel, Switzerland) · 2025Review
- Role of exosomes in gastrointestinal physiology and pathophysiology.Frontiers in immunology · 2025Review
- TNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBD.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory Bowel Disease (IBD) is a term used to describe a group of disorders characterized by chronic inflammation of the gastrointestinal tract, with Crohn's Disease (CD) and Ulcerative Colitis (UC) being the most common. While still not fully understood, pathogenesis is believed to be multifactorial - the result of an interplay between genetic susceptibility, immune dysregulation and environmental factors that all lead to chronic inflammation and tissue remodeling. Innate immune cells, which orchestrate the initial defense mechanisms and modulate the subsequent immune response, play a central role in disease initiation and progression. This review examines the complex involvement of innate immune cells in IBD, emphasizing their interactions with environmental factors and the gut microbiome. We highlight the importance of microbial dysbiosis and impaired intestinal barrier function in disease pathogenesis, and the role that innate immune cells play not only as first responders, but also as key players in maintaining intestinal barrier integrity and gut microbiome. This review provides a comprehensive summary of the role that innate immune cells play in IBD pathogenesis with emphasis on the increasingly recognized role of the gut microbiome. A better understanding of innate immune cell mechanisms and of microbiome-immune interactions is key for the development of novel targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.